Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Expanded Indication for Celltrion’s AVTOZMA | Contract Pharma

What are you searching for?

Sign in
Breaking News

FDA Approves Expanded Indication for Celltrion’s AVTOZMA

AVTOZMA IV now aligns with all indications approved for ACTEMRA IV in the United States.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

The U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of Celltrion’s AVTOZMA (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older.

Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA IV in the United States.

“We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics